SURREY, BC / ACCESSWIRE / February 28, 2022 / Eversio Wellness Ltd. ("Eversio" or the "Company"), a privately owned and operated Canadian company with a Health Canada issued Controlled Substances Dealer's Licence, is pleased to announce that they have successfully developed four products of various dosages that have been third party lab verified to consistently contain 1.5% psilocybin. These standardized GMP compliant natural psilocybin products are ready for distribution to researchers, clinical trials, or patients approved for treatment through Health Canada's Special Access Program.
"Today we have achieved the goal we set out to reach two years ago when we began this journey as a privately owned and operated business with big dreams to make a change in available options for healthcare in Canada," said Craig Garden, Co-founder & CEO, Eversio. "Our mission has always been to change lives through fungi. We believe that there is something unique about natural medicine from a real mushroom that you just can't get from anything synthetic. We couldn't be more proud of our talented team of scientists, including mycologist Dr. Ludovic Le Renard. PhD, and microbiologist Garnet Martens, MSc. for the hard work they have put it to bring this new category of natural medicines to those in need."
ABOUT EVERSIO WELLNESS LTD.
Eversio Wellness is an expanding mushroom wellness company with a mission to change lives through fungi. Our hope is to foster a world that seeks natural options to help treat the root cause of physical and mental health conditions. We are advocates for overcoming stigma and unlocking the healing powers of the many natural compounds inside psychedelic mushrooms for all. www.eversiowellness.com, www.eversiolabs.com.
CONTACT:
Craig Garden, Co-Founder and CEO, Eversio Wellness Ltd.
craigg@eversiowellness.com
778.608.4200
FORWARD-LOOKING INFORMATION
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the Company's ability to bring its products to commercial production, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.
SOURCE: Eversio Wellness Ltd.
View source version on accesswire.com:
https://www.accesswire.com/690765/Eversio-Wellness-Announces-the-Successful-Development-of-Standardized-Natural-Psilocybin-Products-Ready-for-Patients-in-Trials-or-Health-Canadas-SAP
Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an update on its supplemental New Drug Application submission based on the Phase 3 SIENDO study data of selinexor as front-line maintenance therapy following chemotherapy in advanced or recurrent endometrial cancer. The cmpany received feedback that the current SIENDO study topline results would not support an sNDA approval. Karyopharm and the FDA participants had differing views on the study significance and overall clinical benefit
Which stocks are either a fan favorite or a must-avoid? Penny stocks. These tickers going for less than $5 apiece are particularly divisive on Wall Street, with those in favor as well as the naysayers laying out strong arguments. These names are too appealing for the risk-tolerant investor to ignore. Given the low prices, you get more for your money. On top of this, even minor share price appreciation can translate to massive percentage gains, and thus, major returns for investors. However, ther
If certain predetermined financial milestones are met, the deal could be worth up to $1 billion for Syndesi Therapeutics shareholders.
President Joe Biden said Tuesday that someone who has tested positive for the virus will be able to get antiviral pills during the same visit at no cost.
EVELYN HOCKSTEINRep. Lauren Boebert (R-CO) attempted to make Tuesday night’s State of the Union address all about herself—only to get booed by her colleagues as President Joe Biden solemnly talked about his son dying of cancer and military veterans suffering from burn pit exposure.Towards the end of his speech, the president turned his attention to an issue that has drawn bipartisan support and attention: increased care for soldiers who have suffered the effects of toxic exposure.As he announced
The 3-year partnership will offer Omega's operators access to MyndVR's network of content, VR headsets, and proprietary care tablets.
Think Research Corporation (TSXV: THNK) ("Think" or the "Company"), a company focused on transforming healthcare through digital health software solutions, is pleased to announce its subsidiary Clinic 360 Inc. ("Clinic 360") has entered into a patient-sharing arrangement with Peel Weight Loss Clinic to better meet the needs of its gastric sleeve patients.
Shares of the clinical-stage biotech Axsome Therapeutics (NASDAQ: AXSM) are up by a healthy 14.3% as of 1:22 p.m. ET on Tuesday. The drugmaker's shares are pushing higher today in response to the company's 2021 fourth-quarter and full results. The Food and Drug Administration (FDA) has held off on making a final call regarding AXS-05's MDD regulatory review for over five months now due to two technical issues.
How to massage your stomach and abdomen to help you poop and get rid of constipation.
Shares of Pfizer Inc. gained 0.6% in premarket trading on Wednesday after the company said its experimental respiratory syncytial virus (RSV) vaccine had received a breakthrough therapy designation from the Food and Drug Administration. The vaccine candidate is being evaluated in pregnant women to see if it can prevent illness among infants up to until the age of 6 months old. Several drug makers are developing RSV vaccines, including Moderna Inc. and GlaxoSmithKline , though GSK this week halte
The U.S. drug overdose crisis continues unabated, driven by the coronavirus pandemic and the powerful synthetic opioid fentanyl.
A small study of patients suffering from persistent symptoms long after a bout of COVID-19 found that nearly 60% had nerve damage possibly caused by a defective immune response, a finding that could point to new treatments, U.S. researchers reported on Tuesday. The study involved in depth exams of 17 people with so-called long COVID, a condition that arises within three months of a COVID-19 infection and lasts at least two months. "I think what's going on here is that the nerves that control things like our breathing, blood vessels and our digestion in some cases are damaged in these long COVID patients," said Dr. Anne Louise Oaklander, a neurologist at Massachusetts General Hospital and a lead author on the study published in Neurology: Neuroimmunology & Neuroinflammation.
Thank you, and good afternoon, everyone, and welcome to Atea Pharmaceuticals' fourth quarter and full year 2021 financial results conference call. With me today from Atea are chief executive officer and founder, Dr.
Check out the effect one or two drinks a night can have on your body.
Some nights, you toss and turn to get comfortable enough to fall asleep. On others, you may be so exhausted that you barely hit the sheets before you're out cold. But no matter what happens at the end of each day, our focus is usually so set on actually drifting off that we pay very little attention to how we're lying down when we go to bed. And while it might seem like the worst that can come of dozing off the wrong way is a sore neck or spine, studies have found that sleeping in one specific p
It's going to get a lot easier to get treated for COVID-19, as soon as you know you have it, after President Biden announced the launch of the "Test to Treat" initiative.
More than 140 million Americans have had the coronavirus, according to estimates from blood tests that reveal antibodies from infection – about double the rate regularly cited by national case counts. The estimates, compiled by the Centers for Disease Control and Prevention, show that about 43% of the country has been infected by the virus. The study shows that the majority of children have also been infected.Subscribe to The Post Most newsletter for the most important and interesting stories fr
Hong Kong’s leader on Wednesday said people’s movements may be restricted during mandatory testing this month of the entire population for the coronavirus, as health officials reported a record 55,353 daily infections and over a hundred deaths. Chief executive Carrie Lam said authorities are still refining the plan, but that there would be no “complete” lockdown that would prevent entry and exit from the city. “The extent of it must take into account Hong Kong’s circumstances and people’s needs,” she told reporters.
Shares of Gilead Sciences Inc. were down 1.0% in premarket trading on Tuesday after the company said it received a complete response letter from the Food and Drug Administration regarding its application for an experimental HIV drug. Gilead is seeking FDA approval for lenacapavir, a long-acting HIV-1 capsid inhibitor, for people with multi-drug resistant HIV. The FDA raised questions about the use of a specific type of vial and whether it's compatible with the drug solution. Gilead said it will
Were you diagnosed with any of these conditions from age 11 to 15? Here's what you need to know.
